0812 GMT - Fresenius Medical Care's revenue estimates have been lowered by Jefferies due to constrained U.S. volume growth compared to prepandemic levels and a diverging growth outlook from U.S. rival DaVita, its analysts write. The German dialysis provider guides for 0.5% U.S. volume growth in 2025 and expects volumes to recover by 2% in 2026. On the contrary, DaVita guides for flat volume growth at the midpoint of its guidance in 2025 and refrained from long-term comments, hinting at a potentially slower growth across the market. Consequently, Jefferies lowers its 2025-29 revenue estimate but increases its adjusted EBIT target on the company's higher margins and raised savings ambitions. Jefferies analysts look for more updates on its strategy and future growth prospects at its June CMD, they add. Shares fall 0.9% to 45.07 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 21, 2025 04:19 ET (08:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。